The FDA has approved insulin lispro injection (Admelog) to improve glucose control in patients ages three years and older with type 1 diabetes and adult patients with type 2 diabetes, the agency announced Dec. 11, 2017.
The drug is the first short-acting insulin to be approved as a “follow-on” or “me-too” product (its approval was partly based on the FDA's finding of safety and effectiveness for Humalog, another insulin lispro injection). It can be administered by subcutaneous injection, subcutaneous infusion, or intravenous infusion.
The most common adverse reactions are hypoglycemia, itching, and rash. Clinicians should monitor potassium levels in patients who are taking the drug and at risk of hypokalemia, the FDA recommended.